This topic contains a solution. Click here to go to the answer

Author Question: The phase of drug testing that determines the pharmacokinetics, toxicity, and safe dose in humans ... (Read 102 times)

bcretired

  • Hero Member
  • *****
  • Posts: 525
The phase of drug testing that determines the pharmacokinetics, toxicity, and safe dose in humans is:
 
  a. Phase one
  b. Phase two
  c. Phase three
  d. Phase four

Question 2

A germ capable of causing disease is called a(n) _______.
 
  a. amoeba
  b. pathologist
  c. free radical
  d. pathogen



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

leahm14

  • Sr. Member
  • ****
  • Posts: 322
Answer to Question 1

a
Rationale: a. The primary purpose of phase one testing is to determine the pharmacokinetics, toxicity, and safe dose in humans.
b. Tthe primary purpose of phase ttwo testing is to find the therapeutic medication level and watch carefully for toxic and side effects.
c. The primary purpose of phase threeItesting is to refine the usual therapeutic dose and to collect relevant data on side effects.
d. The primary purpose of phase Ifour testing involves postmarketing analysis during conditional approval.

Answer to Question 2

d




bcretired

  • Member
  • Posts: 525
Reply 2 on: Jul 3, 2018
:D TYSM


vickyvicksss

  • Member
  • Posts: 351
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

Egg cells are about the size of a grain of sand. They are formed inside of a female's ovaries before she is even born.

Did you know?

Long-term mental and physical effects from substance abuse include: paranoia, psychosis, immune deficiencies, and organ damage.

Did you know?

Since 1988, the CDC has reported a 99% reduction in bacterial meningitis caused by Haemophilus influenzae, due to the introduction of the vaccine against it.

Did you know?

In the United States, congenital cytomegalovirus causes one child to become disabled almost every hour. CMV is the leading preventable viral cause of development disability in newborns. These disabilities include hearing or vision loss, and cerebral palsy.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library